IMvigor130 Shows Improvement in PFS with Atezolizumab in Metastatic Urothelial Carcinoma
October 10th 2019Enrique Grande, MD, discusses the characteristics of metastatic urothelial cancer, which rationalizes the use of atezolizumab in combination with platinum-based chemotherapy in the IMvigor130 trial, in patients with locally advanced or metastatic urothelial carcinoma.<br />
Watch
Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian Cancers
October 8th 2019Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.
Watch
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch
Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma
October 3rd 2019Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with <em>BRAF V600</em>–mutant unresectable or metastatic melanoma.
Watch
Enrolling Patients With Lung Cancer into Clinical Trials for Immunotherapy
October 2nd 2019Paul A. Bunn, Jr., MD, discusses subsets of patients with lung cancer that can benefit more from enrolling on clinical trials with immunotherapy compared with patients who do not benefit as much from immunotherapeutic approaches. Immunotherapy does not work in every patient, Bunn notes.
Watch
Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma
September 27th 2019Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.
Watch
Expert Discusses Safety Profile from the ENZAMET Trial
September 27th 2019Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events associated with adding enzalutamide or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET trial.<br />
Watch
Identification of Actionable Mutations Remains an Unmet Need in CRC
September 26th 2019Gulam A. Manji, MD, PhD, discusses the need to identify mutations that may be actionable in patients with colorectal cancer. The identification of such mutations can further impact patient survival and improve efficacy, says Manji, in both CRC and other gastrointestinal cancers.
Watch
Adverse Events Inform Treatment Decisions in HCC for Frontline Lenvatinib Versus Sorafenib
September 25th 2019David J. Pinato, MD, PhD, discusses the approach to selecting the appropriate frontline agent for patients with hepatocellular carcinoma. Sorafenib has been around for many years, but now that lenvatinib is FDA approved as well, physicians can now choose between the 2 agents.
Watch
Considering Fedratinib or Ruxolitinib in the Frontline Setting for Treatment of Myelofibrosis
September 24th 2019Ruben Mesa, MD, discusses his experience with fedratinib since its FDA approval for the treatment of patients with myelofibrosis. The agent is compared across trials with ruxolitinib, which has been approved for several years in this space.
Watch
Curative and Palliative Treatment Options for Patients With Hepatocellular Carcinoma
September 22nd 2019Amit Singal, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference.
Watch
Expert Discusses the Role of PD-L1 Expression as a Predictive Biomarker in Urothelial Carcinoma
September 20th 2019Robert Dreicer, MD, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.
Watch
Histologic Type Distinguishes Indolent Thyroid Cancers from More Aggressive Disease
September 19th 2019Andrew Turk, MD, discusses the main factors that can be used to determine whether a patient presenting with thyroid cancer has an indolent form of the disease or a more aggressive thyroid cancer.
Watch